Silvia Guionaud

Hampshire International Business Park
Basingstoke, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Spontaneous clinical and anatomical pathology findings in SDRG rats.

Spontaneous clinical and anatomical pathology findings in SDRG rats.

Journal: Veterinary pathology

Published: March 05, 2026

Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis.

Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis.

Journal: Nature metabolism

Published: June 02, 2020

Innovations, challenges, and minimal information for standardization of humanized mice.

Innovations, challenges, and minimal information for standardization of humanized mice.

Journal: EMBO molecular medicine

Published: December 14, 2019

Nonalcoholic steatohepatitis severity is defined by a failure in compensatory antioxidant capacity in the setting of mitochondrial dysfunction.

Nonalcoholic steatohepatitis severity is defined by a failure in compensatory antioxidant capacity in the setting of mitochondrial dysfunction.

Journal: World journal of gastroenterology

Published: January 17, 2018

Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.

Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.

Journal: Molecular metabolism

Published: April 28, 2017

Inhibition of T-cell activation by the CTLA4-Fc Abatacept is sufficient to ameliorate proteinuric kidney disease.

Inhibition of T-cell activation by the CTLA4-Fc Abatacept is sufficient to ameliorate proteinuric kidney disease.

Journal: American journal of physiology. Renal physiology

Published: March 24, 2016

The Far Side of Vascular Injury: Nonconventional Vasoconstrictors, DNA-targeting Agents, and Agents Toxic to Vascular Smooth Muscle.

The Far Side of Vascular Injury: Nonconventional Vasoconstrictors, DNA-targeting Agents, and Agents Toxic to Vascular Smooth Muscle.

Journal: Toxicologic pathology

Published: September 11, 2015

Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part I. Biotherapeutics.

Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part I. Biotherapeutics.

Journal: Toxicologic pathology

Published: February 28, 2015

Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part 2. Antisense Oligonucleotides.

Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part 2. Antisense Oligonucleotides.

Journal: Toxicologic pathology

Published: February 27, 2015

Nonclinical safety biomarkers of drug-induced vascular injury: current status and blueprint for the future.

Nonclinical safety biomarkers of drug-induced vascular injury: current status and blueprint for the future.

Journal: Toxicologic pathology

Published: April 30, 2014

Translation strategy for the qualification of drug-induced vascular injury biomarkers.

Translation strategy for the qualification of drug-induced vascular injury biomarkers.

Journal: Toxicologic pathology

Published: April 29, 2014

Pharmacokinetics and safety in cynomolgus monkeys of a monoclonal antibody targeting human scavenger receptor class B type-1 for hepatitis C treatment.

Pharmacokinetics and safety in cynomolgus monkeys of a monoclonal antibody targeting human scavenger receptor class B type-1 for hepatitis C treatment.

Journal: Antiviral therapy

Published: March 03, 2013

Showing 1-12 of 12

Last Updated: 09/26/2026